Microsoft word - ndd report final.doc

IMS Therapy Report
Neurodegenerative Disease
IMS THERAPY REPORT
Neurodegenerative Disease
2005 IMS Health Incorporated or its affiliates. All rights reserved.
Neurodegenerative Disease
IMS Therapy Report
NW1 6JB, UK Tel: +44 (0)20 7393 5888, Fax: +44 (0)20 7393 5346 [email protected] http://www.imshealth.com The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions. This Information Service is provided to the client on a personal basis under a non-exclusive and non-transferable licence for the Client’s own direct benefit and use only, and may not be copied or divulged to any other party. Whilst every possible care has been taken in the preparation of this information, the publishers do not hold themselves responsible for any expressions of opinion or error or omission, or any action resulting there from. 2005 IMS Health Incorporated or its affiliates. All rights reserved. 2005 IMS Health Incorporated or its affiliates. All rights reserved.
IMS Therapy Report
Neurodegenerative Disease
Table of Contents
DATA DEFINITIONS AND SOURCES
Sales Data and Exchange Rates
Other Sources
Manufacturers and Brands
IMS Health
The MIDAS Database System
EXECUTIVE SUMMARY
Neurodegenerative Disease Market Key Findings
Anti-Alzheimer Products Market Key Findings
Anti-Parkinson Products Market Key Findings
The Threat of NDD
Treatment
The Global Market
Anti-Alzheimer Products Market by Region Anti-Parkinson Products Market by Region Late-stage R&D
The Future
The Future of the Anti-Alzheimer Products Market The Future of the Anti-Parkinson Products Market 2005 IMS Health Incorporated or its affiliates. All rights reserved.
Neurodegenerative Disease
IMS Therapy Report
1.0 DISEASE OVERVIEW
1.1 Definition of Neurodegenerative Disease
1.1.2 Alzheimer’s Disease and Down’s Syndrome 1.1.3 Parkinson’s Disease and Parkinsonism 1.1.7 Consequences of Neurodegenerative Disease 1.2 Diagnosis & Treatment
1.2.1 Diagnosis and Treatment of Alzheimer’s Disease 1.2.2 Diagnosis and Treatment of Parkinson’s Disease and Parkinsonism 1.2.3 Diagnosis and Treatment of Other Neurodegenerative Diseases 1.3 The Costs of Neurodegenerative Disease
1.3.1 The Cost-effectiveness of NDD Products 2.0 EPIDEMIOLOGY
2.1 Neurological Care Resources
2.2 The Global Burden of Neurodegenerative Diseases
2.2.1 Impact of Alzheimer’s Disease on Mortality and Life Expectancy 2.2.2 Impact of Parkinson’s Disease on Mortality and Life Expectancy 3.0 NEURODEGENERATIVE DISEASE DRUG CLASSES
3.1 Global Drug Classes
3.2 Definition of Anti-Alzheimer Drug Sub-classes
3.3 Definition of Anti-Parkinson Drug Sub-classes
2005 IMS Health Incorporated or its affiliates. All rights reserved.
IMS Therapy Report
Neurodegenerative Disease
4.0 LEADING PRODUCTS IN THE GLOBAL MARKET
4.1 Global Product Sales
4.1.1 Leading Global Anti-Alzheimer Products 4.1.2 Top 20 Global Anti-Parkinson Products 4.2 Anti-Alzheimer Product Profiles
4.3 Anti-Parkinson Product Profiles
5.0 LEADING GLOBAL MANUFACTURERS
5.1 Global Neurodegenerative Disease Product Manufacturer Sales
5.2 Global Anti-Alzheimer Product Manufacturer Sales
5.2.1 Total Global Sales by Manufacturer 5.3 Global Anti-Parkinson Product Manufacturer Sales
5.3.1 Total Global Sales by Manufacturer 5.4 Sales Comparisons of the Leading NDD Manufacturers
5.4.1 Sales Comparison of Leading Anti-Alzheimer Product Manufacturers 5.4.2 Sales Comparison of Leading Anti-Parkinson Product Manufacturers 5.5 Profiles of the Leading Manufacturers
2005 IMS Health Incorporated or its affiliates. All rights reserved.
Neurodegenerative Disease
IMS Therapy Report
6.0 OVERVIEW OF NATIONAL MARKETS FOR NEURODEGENERATIVE
DISEASE PRODUCTS
6.1 Neurodegenerative Disease Product Sales in Selected Markets
6.2 Anti-Alzheimer Product Sales in Selected Markets
6.2.1 Comparison of Anti-Alzheimer Product Sales in Selected Markets 6.2.2 Anti-Alzheimer Product Sales as a Proportion of National Pharmaceutical Markets 6.3 Anti-Parkinson Product Sales in Selected Markets
6.3.1 Comparison of Anti-Parkinson Product Sales in Selected Markets 6.3.2 Anti-Parkinson Product Sales as a Proportion of National Pharmaceutical Markets 7.0 THE BRAZILIAN MARKET
7.1 Pharmaceutical Market Background
7.2 The Brazilian Anti-Alzheimer Products Market
7.3 The Brazilian Anti-Parkinson Products Market
8.0 THE CANADIAN MARKET
8.1 Pharmaceutical Market Background
8.2 The Canadian Anti-Alzheimer Products Market
8.3 The Canadian Anti-Parkinson Products Market
9.0 THE FRENCH MARKET
9.1 Pharmaceutical Market Background
9.2 The French Anti-Alzheimer Products Market
9.3 The French Anti-Parkinson Products Market
2005 IMS Health Incorporated or its affiliates. All rights reserved.
IMS Therapy Report
Neurodegenerative Disease
10.0 THE GERMAN MARKET
10.1 Pharmaceutical Market Background
10.2 The German Anti-Alzheimer Products Market
10.3 The German Anti-Parkinson Products Market
11.0 THE ITALIAN MARKET
11.1 Pharmaceutical Market Background
11.2 The Italian Anti-Alzheimer Products Market
11.3 The Italian Anti-Parkinson Products Market
12.0 THE JAPANESE MARKET
12.1 Pharmaceutical Market Background
12.2 The Japanese Anti-Alzheimer Products Market
12.3 The Japanese Anti-Parkinson Products Market
13.0 THE MEXICAN MARKET
13.1 Pharmaceutical Market Background
13.2 The Mexican Anti-Alzheimer Products Market
13.3 The Mexican Anti-Parkinson Products Market
2005 IMS Health Incorporated or its affiliates. All rights reserved.
Neurodegenerative Disease
IMS Therapy Report
14.0 THE SPANISH MARKET
14.1 Pharmaceutical Market Background
14.2 The Spanish Anti-Alzheimer Products Market
14.3 The Spanish Anti-Parkinson Products Market
15.0 THE UK MARKET
15.1 Pharmaceutical Market Background
15.2 The UK Anti-Alzheimer Products Market
15.3 The UK Anti-Parkinson Products Market
16.0 THE US MARKET
16.1 Pharmaceutical Market Background
16.2 The US Anti-Alzheimer Products Market
16.3 The US Anti-Parkinson Products Market
17.0 RESEARCH & DEVELOPMENT
17.1 Anti-Alzheimer Products in Development
17.1.1 Profiles of Leading Anti-Alzheimer Products in Development 17.2 Anti-Parkinson Products in Development
17.2.1 Profiles of Leading Anti-Parkinson Products in Development 18.0 THE FUTURE OF NEURODEGENERATIVE DISEASE
TREATMENTS MARKETS
18.1 Aggregate Event-based Forecasts
18.2 Canada
2005 IMS Health Incorporated or its affiliates. All rights reserved.
IMS Therapy Report
Neurodegenerative Disease
18.2.1 Diagnosis and Prescribing Profiles 18.2.3 The Future of the Canadian Anti-Alzheimer Products Market 18.2.4 The Future of the Canadian Anti-Parkinson Products Market 18.3 France
18.3.1 Diagnosis and Prescribing Profiles 18.3.3 The Future of the French Anti-Alzheimer Products Market 18.3.4 The Future of the French Anti-Parkinson Products Market 18.4 Germany
18.4.1 Diagnosis and Prescribing Profiles 18.4.3 The Future of the German Anti-Alzheimer Products Market 18.4.4 The Future of the German Anti-Parkinson Products Market 18.5 Italy
18.5.1 Diagnosis and Prescribing Profiles 18.5.3 The Future of the Italian Anti-Alzheimer Products Market 18.5.4 The Future of the Italian Anti-Parkinson Products Market 18.6 Japan
18.6.1 Diagnosis and Prescribing Profiles 18.6.3 The Future of the Japanese Anti-Alzheimer Products Market 18.6.4 The Future of the Japanese Anti-Parkinson Products Market 18.7 Spain
18.7.1 Diagnosis and Prescribing Profiles 18.7.3 The Future of the Spanish Anti-Alzheimer Products Market 18.7.4 The Future of the Spanish Anti-Parkinson Products Market 18.8 The UK
18.8.1 Diagnosis and Prescribing Profiles 18.8.3 The Future of the UK Anti-Alzheimer Products Market 18.8.4 The Future of the UK Anti-Parkinson Products Market 18.9 The US
18.9.1 Diagnosis and Prescribing Profiles 18.9.3 The Future of the US Anti-Alzheimer Products Market 18.9.4 The Future of the US Anti-Parkinson Products Market 18.10 The Future of the Global Neurodegenerative Disease
Products Markets
18.10.1 The Future of the Global Anti-Alzheimer Products Market 18.10.2 The Future of the Global Anti-Parkinson Products Market 2005 IMS Health Incorporated or its affiliates. All rights reserved.
Neurodegenerative Disease
IMS Therapy Report
19.0 OPINIONS ON THE FUTURE OF THE NEURODEGENERATIVE
DISEASE PRODUCTS MARKET
19.1 NICE Committee Holds Key to Development of UK
Anti-Alzheimer Products Market
19.2 What is the Future of Parkinson’s Patient Care in the UK?
19.3 The Challenges and Holy Grails of Alzheimer’s research
19.4 Future Pricing Trends in the EU Market for Neurodegenerative
Disease Products
19.5 The Future of the US Neurodegenerative Disease
Products Markets
19.6 The Current and Future State of Parkinson’s Disease
Care in the US
2005 IMS Health Incorporated or its affiliates. All rights reserved.

Source: http://www.imstherapyreports.com/Media/IMS_Therapy_Rep_TOC_ndd.pdf